CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy Surgery Does Not Improve Survival in Patients With Isolated Severe Tricuspid Regurgitation Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes Non-obstructive High-Risk Plaques Increase the Risk of Future Culprit Lesions Comparable to Obstructive Plaques Without High-Risk Features: The ICONIC Study Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: rationale, design, and baseline patient characteristics. Cost-Effectiveness of Different Durations of Dual-Antiplatelet Use After Percutaneous Coronary Intervention Plaque composition by intravascular ultrasound and distal embolization after percutaneous coronary intervention
|<<... 70 71 72 73 74 75 76 ...>>|

Original ResearchDOI: 10.4244/EIJ-D-19-01006

JOURNAL：EuroIntervention. Article Link

Association between Coronary Collaterals and Myocardial Viability in Patients with a Chronic Total Occlusion

SP Schumacher; H Everaars; WJ Stuijfzand et al. Keywords: coronary collaterals; coronary collaterals; coronary collaterals; CTO

FULL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top